{"organizations": [], "uuid": "f5a8d99c076510d52761d77668e13317b68cb237", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180412.html", "section_title": "Archive News &amp; Video for Thursday, 12 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-us-fda-finalizes-guidances-for-nex/brief-u-s-fda-finalizes-guidances-for-next-generation-sequencing-based-tests-idUSFWN1RP0V6", "country": "US", "domain_rank": 408, "title": "BRIEF-U.S. FDA Finalizes Guidances For Next Generation Sequencing Based Tests", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.981, "site_type": "news", "published": "2018-04-12T22:29:00.000+03:00", "replies_count": 0, "uuid": "f5a8d99c076510d52761d77668e13317b68cb237"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-us-fda-finalizes-guidances-for-nex/brief-u-s-fda-finalizes-guidances-for-next-generation-sequencing-based-tests-idUSFWN1RP0V6", "ord_in_thread": 0, "title": "BRIEF-U.S. FDA Finalizes Guidances For Next Generation Sequencing Based Tests", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12 (Reuters) - FDA:\n* U.S. FDA FINALIZES GUIDANCES TO ACCELERATE THE DEVELOPMENT OF RELIABLE, BENEFICIAL NEXT GENERATION SEQUENCING-BASED TESTS\n* GUIDANCES PROVIDE RECOMMENDATIONS FOR DESIGNING, DEVELOPING, VALIDATING TESTS THAT USE NEXT GENERATION SEQUENCING\n* FIRST GUIDANCE IS TEST DEVELOPERS MAY RELY ON CLINICAL EVIDENCE FROM FDA-RECOGNIZED PUBLIC DATABASES TO SUPPORT CLINICAL CLAIMS FOR TESTS\n* SECOND GUIDANCE DESCRIBES WHAT FDA WOULD LOOK FOR IN PREMARKET SUBMISSIONS TO DETERMINE A TESTâ€™S ANALYTICAL VALIDITY Source text : ( bit.ly/2qvvf9E )\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "http://bit.ly/2qvvf9E", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-12T22:29:00.000+03:00", "crawled": "2018-04-13T17:54:54.028+03:00", "highlightTitle": ""}